Given PARP1’s critical function in cells that mediate anti-tumor immunity, along with reported adverse effects of PARPi treatment such as hematological toxicities [81,82], it seems to be imperative to investigate the direct and immediate effect of PARP inhibitors on immune cells within the context of cancer therapy in greater detail. The gene discussed is PARP1; the disease is cancer.